ABSTRACT
Objective To evaluate the efficacy of Tenghuang-Jiangu tablet combined with osteopeptide injection in the treatment of lumbar hyperosteogeny. Methods A total of 106 patients with lumbar hyperosteogeny were randomly divided into two groups, 53 in each group by digital table method. The control group was treated with osteopeptide injection, and the study group was treated with Tenghuang-Jiangu tablet on the basis of the control group. Both groups were treated for 45 days. The traditional Chinese medcine (TCM) symptoms were scored from pain, numbness, swelling, flexion and extension before and after treatment. The levels of thromboxane B2 (TXB2) and 6-ketone prostaglandin Flα ( 6-Keto-PGFlα ) in serum were detected by ELISA. Adverse reactions during treatment were recorded. Results The total effective rate was 86.8% (46/53) in the study group and 64.2% (34/53) in the control group. There were significant differences between the two groups (χ2=7.338, P=0.007). After treatment, the serum TXB2 (128.01 ± 23.68 pg/ml vs. 172.26 ± 19.33 pg/ml, t=10.539) level in the study group was significantly lower than control group (P<0.01); the serum 6-Keto-PGFlα (36.84 ± 4.96 pg/ml vs. 25.44 ± 4.21 pg/ml, t=12.757) level was significantly higher than control group (P<0.01). After treatment, the scores of pain, numbness, swelling, flexion and extension in the study group were significantly lower than those in the control group (t=10.061, 11.449, 14.921, 15.527, P<0.01). During the treatment period, the incidence of adverse reactions was 17.0% (9/53) in the control group and 22.6% (12/53) in the study group. There was no significant difference between the two groups (χ2=0.534, P=0.465). Conclusions The Tenghuang-Jiangu tablet combined with osteopeptide injection can improve the clinical symptoms of patients with lumbar hyperosteogeny, and regulate the serum levels of TXB2 and 6-Keto-PGFlα.
ABSTRACT
Objective@#To evaluate the efficacy of Tenghuang-Jiangu tablet combined with osteopeptide injection in the treatment of lumbar hyperosteogeny.@*Methods@#A total of 106 patients with lumbar hyperosteogeny were randomly divided into two groups, 53 in each group by digital table method. The control group was treated with osteopeptide injection, and the study group was treated with Tenghuang-Jiangu tablet on the basis of the control group. Both groups were treated for 45 days. The traditional Chinese medcine (TCM) symptoms were scored from pain, numbness, swelling, flexion and extension before and after treatment. The levels of thromboxane B2 (TXB2) and 6-ketone prostaglandin Flα ( 6-Keto-PGFlα ) in serum were detected by ELISA. Adverse reactions during treatment were recorded.@*Results@#The total effective rate was 86.8% (46/53) in the study group and 64.2% (34/53) in the control group. There were significant differences between the two groups (χ2=7.338, P=0.007). After treatment, the serum TXB2 (128.01 ± 23.68 pg/ml vs. 172.26 ± 19.33 pg/ml, t=10.539) level in the study group was significantly lower than control group (P<0.01); the serum 6-Keto-PGFlα (36.84 ± 4.96 pg/ml vs. 25.44 ± 4.21 pg/ml, t=12.757) level was significantly higher than control group (P<0.01). After treatment, the scores of pain, numbness, swelling, flexion and extension in the study group were significantly lower than those in the control group (t=10.061, 11.449, 14.921, 15.527, P<0.01). During the treatment period, the incidence of adverse reactions was 17.0% (9/53) in the control group and 22.6% (12/53) in the study group. There was no significant difference between the two groups (χ2=0.534, P=0.465).@*Conclusions@#The Tenghuang-Jiangu tablet combined with osteopeptide injection can improve the clinical symptoms of patients with lumbar hyperosteogeny, and regulate the serum levels of TXB2 and 6-Keto-PGFlα.
ABSTRACT
Objective To study the effects of Jiangu tablet on articular chondrocyte apoptosis in T-2 toxin poisoning rats. Methods According to random number table, fifty weaning male SD rats were divided into two groups by body mass, i.e., 10 for normal control group and 40 for T-2 toxin group (intragastric administration of distilled water or T-2 toxin 200 ng·g-1·d-1) for 30 days. Then the T-2 toxin group was divided into T-2 toxin group, Jiangu tablet low-dose group, middle-dose group and high-dose group treating with 3 ml of T-2 toxin 200 ng or different concentration of Jiangu tablet (contain 1.562 5, 3.125 0 and 6.250 0 g Jiangu tablet active compound). Each group had 10 rats and was given T-2 toxin or different amount of Jiangu tablet for 30 days. Then the rats were killed. The articular cartilage was removed from rats and RNA was extracted from the articular cartilage by Trizol. The mRNA expressions of p53, Bax, Bcl-2 and cysteinyl aspartate specific proteinase(caspase)-3 were detected by real-time PCR. Results The mRNA expressions of p53, Bax, Bcl-2 and caspase-3 in normal control group, T-2 toxin group, Jiangu tablet low-dose group, middle-dose group and high-dose group were: 1.00 ± 0.98, 200.37 ± 30.39, 180.19 ± 28.14, 120.25 ± 15.35, 50.34 ± 10.12;1.00 ± 0.98, 185.37 ± 10.15, 152.59 ± 15.23, 108.46 ± 9.14, 57.18 ± 1.31; 1.00 ± 0.99,0.22 ± 0.03, 0.28 ± 0.06, 0.43 ± 0.08, 0.58 ± 0.04; 1.00 ± 0.97, 209.55 ± 25.64, 152.38 ± 15.46, 120.14 ± 11.52 and 49.24 ± 8.69, respectively. Compared with the normal control group, the mRNA expressions of p53, Bax and caspase-3 were up-regulated in T-2 toxin group, low-dose group, middle-dose group and high-dose group while the mRNA expression of Bc1-2 was down-regulated(all P < 0.05). The mRNA expressions of p53 and caspase-3 in Jiangu tablet high-dose group and middle-dose group were significantly decreased than those in T-2 toxin group (all P<0.05). The mRNA expressions of Bcl-2 in Jiangu tablet high-dose group and middle-dose group were significantly increased than that in T-2 toxin group(all P<0.05). The mRNA expression of Bax in Jiangu tablet high-dose group was significantly decreased than that in T-2 toxin group(P<0.05). Conclusion The Jiangu tablet can significantly inhibit the apoptosis of articular chondrocyte in T-2 toxin poisoning rats.
ABSTRACT
Objective To establish the clinical pharmacokinetics research method for Bawei Jiangu Tablet.Methods Drug blood concentration was estimated through analyzing the ingredients and preclinical pharmaceutical research results of Bawei Jiangu Tablet.Results Corresponding cardiac glycoside value in serum of animals treated with oral use of Bawei Jiangu Tablets and cortex periplocae extracts can be detected by drug monitor system of digoxin immunoreaction, which was similar to that in animals treated with digoxin.Corresponding cardiac glycoside value had also been detetected in serum of subjects in phaseⅠclinical tolerance trial,which was related to the time and dosage of administration.Clini- cal negative control trial showed that the reaction was specific.Conclusion Pharmacokinetics study on target of toxic components with cross-reaction of periplocoside is feasible through drug monitor system of digoxin immunoreaction.